Audrey E. Kitagawa, J.D.

President and Founder

"In the seemingly ordinariness of daily living is the power of transformation. Individual transformation arises out of awareness, and a willingness to change to become a better person right where we are. We each have personal responsibility and collective responsibility to make positive changes here and now."

Background

Naoky Tsai, M.D.

Clinical Professor of Medicine

John A. Burns School of Medicine

Specialty:

Gastroenterology and Transplant Hepatology‍

Special Interests:‍

Chronic Liver Diseases

Chronic Hepatitis B

Hepatobiliary Cancer

NASH‍

Degree: ‍

M.D., Taipei Medical University, Taiwan 

Residency:

Internal Medicine, Yale University Affiliated Residency Program, The Griffin Hospital, Derby, CT

Fellowship:

Gastroenterology, State University of New York, Buffalo General Hospital, Buffalo, NY ‍

Board Certifications:‍

Internal Medicine, Gastroenterology‍

Academic/Company Affiliations:

  • Clinical Professor of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI
  • Primary Physician, Liver Transplant Program, Queens Medical Center, Honolulu Hawaii
  • Gastroenterologist & Hepatologist, Castle Medical Center, Adventist Health, Kailua, HI
  • Medical Adviser, Hawaii Health and Harm Reduction Center

Additional Experience:

  • Member, Steering Committee U.S., Japan Autoimmune Liver Disease Association
  • Member, Scientific Advisory Panel, American Gastroenterological Association
  • Reviewer for the following medical journals: J. Hepatology, J. Clinical Hepatology and Gastroenterology, J. Clinical Infectious Disease, J. Medical Virology, Journal of Clinical Gastroenterology    
  • Helped establish the first liver transplant program in Hawaii at St. Francis Medical Center, Honolulu, HI
  • Member of NIH/NIDDK funded Hepatitis B Clinical Research Network (2008-2018)
  • Member of NCI funded Liver Tumor Translational Research Team, University of Hawaii Cancer Center.

Key Publications:

  • Changes in gastrointestinal microbial communities influence HIV-specific CD8+ T-cell responsiveness to immune checkpoint blockade. SahBandar IN, Chew GM, Corley MJ, Pang APS, Tsai N, Hanks N, Khadka VS, Klatt NR, Hensley-McBain T, Somsouk M, Vujkovic-Cvijin I, Chow DC, Shikuma CM, Ndhlovu LC.AIDS. 2020 Aug 1;34(10):1451-1460. doi: 10.1097/QAD.0000000000002557.PMID: 32675558
  • Maternal knowledge of the risk of vertical transmission and offspring acquisition of hepatitis B.
  • Lisker-Melman M, Khalili M, Belle SH, Terrault NA, Lin HS, Smith CI, Chung RT, Tsai N, Bzowej NH, Tran TT, Schwarzenberg SJ; Hepatitis B Research Network (HBRN).Ann Hepatol. 2020 Jul-Aug;19(4):388-395. doi: 10.1016/j.aohep.2020.04.006. Epub 2020 May 20.PMID: 32507734
  • Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection.Flamm SL, Kort J, Marx SE, Strezewski J, Dylla DE, Bacon B, Curry MP, Tsai N, Wick N.Adv Ther. 2020 May;37(5):2267-2274. doi: 10.1007/s12325-020-01301-5. Epub 2020 Apr 11.PMID: 32279176‍
  • Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication.Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Nader F. Liver Int. 2019 Jun 7. doi: 10.1111/liv.14171. [Epub ahead of print] PMID:31173468‍
  • Tsai N, Bacon B, Curry M, Flamm SL, Milligan S, Wick N, Younossi Z, Afdhal N. Changing demographics among populations prescribed HCV treatment, 2013-2017. Am J Manag Care. 2019 Jul;25(7):319-323.
  • Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Nader F. Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. Liver Int. 2019 Jun 7. doi: 10.1111/liv.14171. [Epub ahead of print]
  • Bzowej NH, Tran TT, Li R, Belle SH, Smith CI, Khalili M, Chung R, Tsai N, Terrault N; Hepatitis B Research Network (HBRN). Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study. Am J Gastroenterol. 2019 May 1. doi: 10.14309/ajg.0000000000000221. [Epub ahead of print]
  • Feld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network (HBRN). Entecavir and peginterferon alfa-2a in adults with HBeAg-positive immune tolerant chronic hepatitis B virus infection. Hepatology. 2018 Dec 14. doi: 10.1002/hep.30417. [Epub ahead of print]. PMID:30549279
  • Younossi ZM, Stepanova M, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Younossi I, Racila A.
  • Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes. Clin Gastroenterol Hepatol. 2018 Mar 2. pii: S1542-3565(18)30225-8. doi: 10.1016/j.cgh.2018.02.037. [Epub ahead of print]
  • Kwee SA, Wong L, Chan OTM, Kalathil S, Tsai N. PET/CT with 18F Fluorocholine as an Imaging Biomarker for Chronic Liver Disease: A Preliminary Radiopathologic Correspondence Study in Patients with Liver Cancer. Radiology. 2018 Jan 9:171333. doi: 10.1148/radiol.2018171333. [Epub ahead of print]. PMID: 29315063
  • Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ. Safety, Efficacy and Pharmacodynamics of Vesatolimod (GS-9620) in Virally-Suppressed Patients with Chronic Hepatitis B. J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32408-X. doi: 10.1016/j.jhep.2017.10.027. [Epub ahead of print]. PMID:28706177
  • Kowdley KV, Sundaram V, Jeon CY, Qureshi K, Latt NL, Sahota A, Lott S, Curry MP, Tsai N, Chaiyakunapruk N, Lee Y, Petersen J, Buggisch P. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology. 2017 Apr;65(4):1094-1103. doi: 10.1002/hep.29005. Epub 2017 Feb 25. Review. PMID:28027579
  • Wong LL, Reyes RJ, Kwee SA, Hernandez BY, Kalathil SC, Tsai NC. Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world? Clin Mol Hepatol. 2017 Jul 14. doi: 10.3350/cmh.2017.0008. [Epub ahead of print]. PMID:28706177
  • Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM, Afdhal NH. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat. 2017 Jan;24(1):22-27. doi: 10.1111/jvh.12611. PMID: 27730717
  • Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM, Afdhal NH. Evaluation of Proton Pump Inhibitor Use on Treatment Outcomes with Ledipasvir and Sofosbuvir in a Real-World Cohort Study. Hepatology. 2016 Aug 17. doi: 10.1002/hep.28782. PMID: 27533287
  • Gane E, Kowdley KV, Pound D, Stedman CA, Davis M, Etzkorn K, Gordon SC, Bernstein D, Everson G, Rodriguez-Torres M, Tsai N, Khalid O, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Tong M, Chung RT, Beavers K, Poulos JE, Kwo PY, Nguyen MH. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with HCV Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial. Gastroenterology. 2016 Jul 30. pii: S0016-5085(16)34834-X. doi: 10.1053/j.gastro.2016.07.038. PMID: 27486033

Organization

Institution

John A. Burns School of Medicine
Visit Website >

Content

No items found.

Background

Audrey E. Kitagawa, JD, is the President/Founder of the International Academy for Multicultural Cooperation, the President of the Light of Awareness International Spiritual Family, the former Advisor to the Office of the Special Representative of the Secretary General for Children and Armed Conflict at the United Nations.

She is a United Nations Representative for the United Religions Initiative, and Chair Emerita of the NGO Committee on Spirituality, Values and Global Concerns, A Committee of the Conference of NGOs in Consultative Relationship with the United Nations. She has been enstooled into the royal family as the Nekoso Hemaa, (i.e. Queen Mother of Development), of Ajiyamanti in Ghana, West Africa, and has a school which she helped to build named after her in her African name, the Nana Ode Anyankobea Junior Secondary School.

She wrote the chapter, Crossing World Views, The Power of Perspective in the Hawaii Japanese American Experience, which was published in a book about multiculturalism, communication and Asian women entitled, Learning In The Light. Her chapter, Globalization As The Fuel For Religious And Ethnic Conflict has been published in the book, Globalization And Identity, Cultural Diversity, Religion and Citizenship. Her article, The Role Of Identity In The Rise And Decline of Buddhism In Hawaii, The 50th State Of The United States Of America, has been published in Sambodhi, a Buddhist Journal. She published articles in World Affairs The Journal Of International Issues, entitled, The Power of Om: Transformation of Consciousness, and Practical Spirituality. She wrote the chapter, The US In Foreign Affairs: Source of Global Security, Or Source of Global Fear? in the book, America & The World The Double Bind. She is currently writing a chapter on Space Ethics for a legal, academic book on Space Law.

She has been listed in Who's Who Of American Law, Who's Who Of American Women, Who's Who In America, Who's Who In The World, and Prominent People of Hawaii. She is the recipient of the Medal “Pride of Eurasia” and a Diploma from the Republic of Kazakhstan Ministry of Education and Science L.N. Gumilyov Eurasian National University for her outstanding contribution to the development of spiritual culture and education in Eurasia. She is the recipient of the Spirit of the UN Award which is given to outstanding individuals who have demonstrated the vision and spirit of the United Nations as expressed through the UN Charter, and the Universal Declaration of Human Rights. She was conferred an Honorary Interfaith Minister degree by the New Seminary.

Naoky Tsai, M.D.

Gastroenterologist, Hepatologist, Clinical Professor of Medicine, John A. Burns School of Medicine, University of Hawai‘i

Biography

Naoky Tsai, M.D.

Clinical Professor of Medicine

John A. Burns School of Medicine

Specialty:

Gastroenterology and Transplant Hepatology‍

Special Interests:‍

Chronic Liver Diseases

Chronic Hepatitis B

Hepatobiliary Cancer

NASH‍

Degree: ‍

M.D., Taipei Medical University, Taiwan 

Residency:

Internal Medicine, Yale University Affiliated Residency Program, The Griffin Hospital, Derby, CT

Fellowship:

Gastroenterology, State University of New York, Buffalo General Hospital, Buffalo, NY ‍

Board Certifications:‍

Internal Medicine, Gastroenterology‍

Academic/Company Affiliations:

  • Clinical Professor of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI
  • Primary Physician, Liver Transplant Program, Queens Medical Center, Honolulu Hawaii
  • Gastroenterologist & Hepatologist, Castle Medical Center, Adventist Health, Kailua, HI
  • Medical Adviser, Hawaii Health and Harm Reduction Center

Additional Experience:

  • Member, Steering Committee U.S., Japan Autoimmune Liver Disease Association
  • Member, Scientific Advisory Panel, American Gastroenterological Association
  • Reviewer for the following medical journals: J. Hepatology, J. Clinical Hepatology and Gastroenterology, J. Clinical Infectious Disease, J. Medical Virology, Journal of Clinical Gastroenterology    
  • Helped establish the first liver transplant program in Hawaii at St. Francis Medical Center, Honolulu, HI
  • Member of NIH/NIDDK funded Hepatitis B Clinical Research Network (2008-2018)
  • Member of NCI funded Liver Tumor Translational Research Team, University of Hawaii Cancer Center.

Key Publications:

  • Changes in gastrointestinal microbial communities influence HIV-specific CD8+ T-cell responsiveness to immune checkpoint blockade. SahBandar IN, Chew GM, Corley MJ, Pang APS, Tsai N, Hanks N, Khadka VS, Klatt NR, Hensley-McBain T, Somsouk M, Vujkovic-Cvijin I, Chow DC, Shikuma CM, Ndhlovu LC.AIDS. 2020 Aug 1;34(10):1451-1460. doi: 10.1097/QAD.0000000000002557.PMID: 32675558
  • Maternal knowledge of the risk of vertical transmission and offspring acquisition of hepatitis B.
  • Lisker-Melman M, Khalili M, Belle SH, Terrault NA, Lin HS, Smith CI, Chung RT, Tsai N, Bzowej NH, Tran TT, Schwarzenberg SJ; Hepatitis B Research Network (HBRN).Ann Hepatol. 2020 Jul-Aug;19(4):388-395. doi: 10.1016/j.aohep.2020.04.006. Epub 2020 May 20.PMID: 32507734
  • Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection.Flamm SL, Kort J, Marx SE, Strezewski J, Dylla DE, Bacon B, Curry MP, Tsai N, Wick N.Adv Ther. 2020 May;37(5):2267-2274. doi: 10.1007/s12325-020-01301-5. Epub 2020 Apr 11.PMID: 32279176‍
  • Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication.Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Nader F. Liver Int. 2019 Jun 7. doi: 10.1111/liv.14171. [Epub ahead of print] PMID:31173468‍
  • Tsai N, Bacon B, Curry M, Flamm SL, Milligan S, Wick N, Younossi Z, Afdhal N. Changing demographics among populations prescribed HCV treatment, 2013-2017. Am J Manag Care. 2019 Jul;25(7):319-323.
  • Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Nader F. Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. Liver Int. 2019 Jun 7. doi: 10.1111/liv.14171. [Epub ahead of print]
  • Bzowej NH, Tran TT, Li R, Belle SH, Smith CI, Khalili M, Chung R, Tsai N, Terrault N; Hepatitis B Research Network (HBRN). Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study. Am J Gastroenterol. 2019 May 1. doi: 10.14309/ajg.0000000000000221. [Epub ahead of print]
  • Feld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network (HBRN). Entecavir and peginterferon alfa-2a in adults with HBeAg-positive immune tolerant chronic hepatitis B virus infection. Hepatology. 2018 Dec 14. doi: 10.1002/hep.30417. [Epub ahead of print]. PMID:30549279
  • Younossi ZM, Stepanova M, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Younossi I, Racila A.
  • Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes. Clin Gastroenterol Hepatol. 2018 Mar 2. pii: S1542-3565(18)30225-8. doi: 10.1016/j.cgh.2018.02.037. [Epub ahead of print]
  • Kwee SA, Wong L, Chan OTM, Kalathil S, Tsai N. PET/CT with 18F Fluorocholine as an Imaging Biomarker for Chronic Liver Disease: A Preliminary Radiopathologic Correspondence Study in Patients with Liver Cancer. Radiology. 2018 Jan 9:171333. doi: 10.1148/radiol.2018171333. [Epub ahead of print]. PMID: 29315063
  • Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ. Safety, Efficacy and Pharmacodynamics of Vesatolimod (GS-9620) in Virally-Suppressed Patients with Chronic Hepatitis B. J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32408-X. doi: 10.1016/j.jhep.2017.10.027. [Epub ahead of print]. PMID:28706177
  • Kowdley KV, Sundaram V, Jeon CY, Qureshi K, Latt NL, Sahota A, Lott S, Curry MP, Tsai N, Chaiyakunapruk N, Lee Y, Petersen J, Buggisch P. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology. 2017 Apr;65(4):1094-1103. doi: 10.1002/hep.29005. Epub 2017 Feb 25. Review. PMID:28027579
  • Wong LL, Reyes RJ, Kwee SA, Hernandez BY, Kalathil SC, Tsai NC. Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world? Clin Mol Hepatol. 2017 Jul 14. doi: 10.3350/cmh.2017.0008. [Epub ahead of print]. PMID:28706177
  • Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM, Afdhal NH. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat. 2017 Jan;24(1):22-27. doi: 10.1111/jvh.12611. PMID: 27730717
  • Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM, Afdhal NH. Evaluation of Proton Pump Inhibitor Use on Treatment Outcomes with Ledipasvir and Sofosbuvir in a Real-World Cohort Study. Hepatology. 2016 Aug 17. doi: 10.1002/hep.28782. PMID: 27533287
  • Gane E, Kowdley KV, Pound D, Stedman CA, Davis M, Etzkorn K, Gordon SC, Bernstein D, Everson G, Rodriguez-Torres M, Tsai N, Khalid O, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Tong M, Chung RT, Beavers K, Poulos JE, Kwo PY, Nguyen MH. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with HCV Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial. Gastroenterology. 2016 Jul 30. pii: S0016-5085(16)34834-X. doi: 10.1053/j.gastro.2016.07.038. PMID: 27486033

Organization

Institution

John A. Burns School of Medicine
Visit Website >

Content

No items found.
No items found.
RETURN TO TOP OF PAGE